SB 321 creates an advisory task force to review and recommend annual adjustments to state reimbursement rates paid to healthcare providers under state contracts. The task force, composed of 6 appointed members (3 by each legislative chamber, representing health professions) plus agency representatives, will assess whether reimbursement rates cover agencies' costs, staff salaries, and administrative expenses for frontline healthcare workers. It must submit annual recommendations by August 1, starting in 2026, focusing on ensuring rates are adequate to support quality care for vulnerable populations. This bill directly affects state-contracted healthcare agencies and providers who serve Medicaid and other state-funded programs.
HB 395, the "Tennessee Genomic Security and End Organ Harvesting Act," prohibits Tennessee health insurers from covering organ transplants or post-transplant care if the organ was sourced from China or procured through sale/donation originating in China. It also bans medical and research facilities from using genetic sequencing equipment or software produced by entities linked to "foreign adversaries" (specifically targeting China per the bill's context), requiring replacement within 180 days. Additionally, the bill mandates that all genetic sequencing data must be stored within the United States, with remote access from outside the country prohibited without approval from the state health commissioner. The law takes effect on January 1, 2026, directly affecting health insurers, hospitals, and research facilities operating in Tennessee.
HB 498 creates an advisory task force to review and recommend annual adjustments to state reimbursement rates paid to healthcare agencies in Tennessee. The task force, composed of 6 appointed members (3 by each legislative chamber, representing different health professions) and ex-officio agency representatives, will focus on ensuring rates cover agency costs, staff salaries, and administrative needs. It must submit annual recommendations by August 1, starting in 2026, to state officials and legislative committees, considering factors like provider costs, staff compensation, and workforce shortages. The bill directly affects healthcare agencies providing state-funded services, aiming to make reimbursement rates more adequate without changing existing funding levels.
HB 502 expands TennCare coverage to include diagnosis (including genetic testing) and treatment for Kleefstra syndrome, a rare genetic disorder affecting development and multiple body systems. It requires TennCare to provide this coverage in the same manner and extent as for autism spectrum disorder, Down syndrome (Trisomy 21), and other similar genetic disorders, when medically necessary. This applies to all enrolled individuals with Kleefstra syndrome and covers therapies, medications, assistive devices, and interventions aimed at improving quality of life. The law takes effect July 1, 2025, after being signed by the Governor in April 2025.
SB 152 allows patients with severe chronic diseases or terminal illnesses to access investigational stem cell treatments (adult stem cell therapies still in clinical trials and not yet FDA-approved) after their doctors confirm other FDA-approved treatments aren't viable. It requires Tennessee’s health commissioner to create rules listing qualifying medical conditions and mandates doctors to document that all standard treatments were considered before recommending these experimental therapies. The bill also protects physicians from license penalties for following these guidelines and prohibits government interference with patient access. This directly affects patients with qualifying conditions and their treating physicians in Tennessee.
HB 236 extends the Bureau of TennCare (Tennessee's Medicaid program) within the Department of Finance and Administration until June 30, 2029, by amending Tennessee Code Sections 4-29-246 and 4-29-250. It removes a sunset provision and formally incorporates the Bureau's structure under Executive Order No. 23 (1999), ensuring its continued operation without future expiration. This bill directly affects the TennCare program's administrative structure and the Department of Finance and Administration's management of Medicaid services. The law became effective March 26, 2025, after Governor approval.
HB 383 requires Tennessee's health commissioner to add alpha-gal syndrome - a rare meat allergy triggered by tick bites - to the state's official list of reportable diseases by July 1, 2025. Healthcare providers must then report diagnosed cases to the Department of Health under existing rules. This bill directly affects medical professionals who will need to submit these reports and public health officials who will track the condition. The law amends Tennessee Code Titles 4, 63, and 68 to implement this change, effective March 26, 2025.
SB 282, the "Individualized Investigational Treatment Act," creates a legal framework for patients with life-threatening or severely debilitating illnesses to access personalized medical treatments (like gene therapies or vaccines tailored to their genetic profile) when standard FDA-approved options have been exhausted. It directly affects eligible patients (who must meet specific criteria including physician attestation and written informed consent) and eligible facilities (those complying with federal human subjects protections). Key provisions require detailed written consent covering all treatment options, risks, and financial liability, while clarifying that insurers, health plans, and providers are **not obligated** to cover these treatments or related costs (TCA §§ 63-6-1304(a)-(d)). The law takes effect July 1, 2025, and explicitly states that heirs cannot be held liable for unpaid treatment debts if a patient dies during treatment (TCA § 63-6-1305).
This bill adds hepatitis C antibody (anti-HCV) testing to the standard blood screening required for all pregnant women in Tennessee during initial prenatal visits and between weeks 28-32 of pregnancy. If the anti-HCV test is reactive, labs must automatically conduct a follow-up HCV RNA test without requiring additional orders. It directly affects all pregnant women receiving routine prenatal care in Tennessee, expanding the required screening panel to include hepatitis C alongside existing tests for syphilis, rubella, and hepatitis B. The changes take effect July 1, 2025, and align hepatitis C testing protocols with existing disease reporting requirements for maternal health.
HB 229 extends the Board of Alcohol and Drug Abuse Counselors' authority until June 30, 2029, by amending Tennessee Code Sections 4-29-246 and 4-29-250. This change removes the board's previous expiration date, allowing it to continue overseeing licensing standards for alcohol and drug counselors. The board, established under Title 68, Chapter 24, will now operate without sunset provisions until the new date.
